Business Information
The group's principal activity is to specialize in the oral delivery of therapeutic macromolecules and other compounds that are not currently deliverable by oral means. The group is focused primarily on developing a form of its anticoagulant/anti thrombotic treatment for cardiovascular disease and heparin. The group has several product candidates in pre clinical and clinical development across a broad range of therapeutic areas such as cardiovascular, osteoporosis, growth disorders, diabetes, asthma/allergies, obesity and anti-infectives. These product candidates include oral heparin solution dose, oral heparin solid dose, oral lmwh solid dose, oral lmwh solution dose, oral salmon calcitonin, oral recombinant parathyroid harmone, oral recombinant human growth harmone, oral insulin, oral cromolyn sodium, oral ciliary neutrophic growth factor and oral daptomycin.
|
|
|
Year |
Sales |
Net Income |
| 2006 | 7,259 | (41,766) | | 2005 | 3,540 | (18,051) | | 2004 | 1,953 | (37,522)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
